Suzuki Takahiro
Division of Hematology, Department of Medicine, Jichi Medical University.
Rinsho Ketsueki. 2015 Oct;56(10):1985-95. doi: 10.11406/rinketsu.56.1985.
Myelodysplastic syndromes (MDS) are myeloid clonal disorders presumably induced by genetic mutations in immature hematopoietic cells. According to the international prognostic scoring system (IPSS or IPSS-R), patients are classified into two groups: lower-risk MDS (LR-MDS) and higher-risk MDS (HR-MDS). A majority of LR-MDS patients manifest refractory cytopenias due to inefficient hematopoiesis, and patients in this group are principally treated with agents stimulating hematopoiesis or differentiation. On the other hand, patients with HR-MDS are at much higher risk of developing leukemia, and thus require prompt hematopoietic stem cell transplantation or chemotherapy. In this section, I will discuss current treatment strategies for MDS in Japan, including future perspectives.
骨髓增生异常综合征（MDS）是一种髓系克隆性疾病，可能由未成熟造血细胞中的基因突变引起。根据国际预后评分系统（IPSS或IPSS-R），患者被分为两组：低危MDS（LR-MDS）和高危MDS（HR-MDS）。大多数LR-MDS患者由于造血功能低下而表现为难治性血细胞减少，该组患者主要接受刺激造血或分化的药物治疗。另一方面，HR-MDS患者发生白血病的风险要高得多，因此需要及时进行造血干细胞移植或化疗。在本节中，我将讨论日本目前针对MDS的治疗策略，包括未来展望。
